0
Abstract: Slide Presentations |

MORTALITY AT 60-MONTH MEAN FOLLOW-UP IN 2057 PATIENTS WITH CORONARY ANGIOGRAPHIC EVIDENCE OF NO CORONARY ARTERY DISEASE OR NONOBSTRUCTIVE CORONARY ARTERY DISEASE OR REVASCULARIZED OBSTRUCTIVE CORONARY ARTERY DISEASE OF 1, 2, AND 3 MAJOR VESSELS FREE TO VIEW

Kiran Chilappa, MD*; Wilbert S. Aronow, MD; Archana Rachdev, MD; Chul Ahn, MD; Kumar Kalapatapu, MD; Anthony L. Pucillo, MD; Craig E. Monsen, MD
Author and Funding Information

New York Medical College, Valhalla, NY


Chest


Chest. 2009;136(4_MeetingAbstracts):6S-g-7S. doi:10.1378/chest.136.4_MeetingAbstracts.6S-g
Text Size: A A A
Published online

Abstract

PURPOSE:  To investigate the 5-year survival of patients with coronary angiographic evidence of no coronary artery disease (CAD), nonobstructive CAD, and revascularized 1-vessel, 2-vessel, and 3-vessel obstructive CAD.

METHODS:  Coronary angiography was performed in 2,057 unselected patients, mean age 69 years (57% men and 43% women), with chest pain.

RESULTS:  Of 2,057 patients, 760 (37%) had obstructive CAD with >50% obstruction of at least 1 major coronary artery and were revascularized, 695 (34%) had nonobstructive CAD (<50% obstruction), and 602 (29%) had normal coronary arteries. At 60 ± 16-month follow-up, all-cause mortality occurred in 41 of 602 patients (7%) with no CAD (group 1), in 80 of 695 patients (12%) with nonobstructive CAD (group 2), in 50 of 302 patients (17%) with revascularized 1-vessel obstructive CAD (group 3), in 47 of 201 patients (23%) with 2-vessel revascularized obstructive CAD (group 4), and in 72 of 257 patients (28%) with 3-vessel revascularized obstructive CAD (group 4). Log-rank tests to compare survival curves among the 5 groups showed p = 0.004 for groups 1 versus 2; p <0.0001 for groups 1 versus 3, 1 versus 4, 1 versus 5, 2 versus 4, and 2 versus 5; and p = 0.007 for groups 3 versus 5.

CONCLUSION:  In conclusion, patients with nonobstructive CAD had a worse survival than those with no CAD, a nonsignificant difference in survival than those with revascularized 1-vessel obstructive CAD, and a better survival than those with revascularized 2-vessel or 3-vessel obstructive CAD.

CLINICAL IMPLICATIONS:  Patients with nonobstructive CAD should be treated with intensive risk factor management as well as with drug therapy recommended for obstructive CAD.

DISCLOSURE:  Kiran Chilappa, No Financial Disclosure Information; No Product/Research Disclosure Information

Monday, November 2, 2009

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543